Loading
A myeloma ADC that was withdrawn in 2022 then came back in 2025 after strong trials in earlier lines.
Belantamab mafodotin is an afucosylated anti-BCMA IgG1 antibody linked through a non-cleavable linker to MMAF, a non-permeable tubulin inhibitor; it kills through the payload and through enhanced antibody-dependent cellular cytotoxicity. It received accelerated approval in 2020 for myeloma after four or more lines (DREAMM-2), was withdrawn in 2022 when DREAMM-3 failed to confirm benefit, and returned in 2025 in the US and EU for relapsed or refractory myeloma after at least one prior line, after DREAMM-7 (with bortezomib and dexamethasone) and DREAMM-8 (with pomalidomide and dexamethasone) showed progression-free and overall survival benefits. Dosing is 2.5 mg/kg every 3 weeks in DREAMM-7 or 2.5 then 1.9 mg/kg every 4 weeks in DREAMM-8. Keratopathy occurs in most patients and carries a boxed warning, so an ophthalmology-based REMS is required.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Afucosylated anti-BCMA IgG1 with MMAF; ADCC plus payload. Connects to BCMA.
1.Antibody binds BCMA on the tumour cell surface
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Source: www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications. Doses are for orientation; the current label governs.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Withdrawn from the US market between 2022 and 2023 and re-approved in 2025 in combination; ocular monitoring under a REMS.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. Plans require documented prior lines and enrolment in the ocular REMS.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA1149. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Adults patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
Accelerated approval, relapsed/refractory myeloma after ≥4 lines (DREAMM-2) source
Withdrawn after DREAMM-3 failed to confirm benefit source
Adults patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
Withdrawn: the indication came off the label 2.5 years after its accelerated approval. source
Complete response letter on combination filing; resubmitted source
Approval in combination regimens for relapsed/refractory myeloma after ≥1 line (DREAMM-7/8) source
| Region | Year | Indication |
|---|---|---|
| US | 2020 | Relapsed myeloma ≥4 lines (accelerated; withdrawn 2022) |
| US | 2025 | Relapsed/refractory myeloma after ≥1 prior line, in combination |
| EU | 2025 | R/R myeloma with BorDex or PomDex; 23 Jul 2025 |
| Adverse event |
|---|
| Keratopathy |
| Thrombocytopenia |
| Blurred vision |
| Dry eye |
| Infections |
Ocular events in most patients; boxed warning. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare Part B (physician-administered); commercial plans per formulary | not disclosed | - |
| United Kingdom | NICE: recommended in combination regimens for relapsed myeloma (2025) | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Belantamab mafodotin" OR ABSTRACT:"Belantamab mafodotin" OR TITLE:"Blenrep" OR ABSTRACT:"Blenrep") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Belantamab mafodotin, not a curated reading list.
Shares Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM, Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple, GSK, Multiple myeloma.
Shares Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM, Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi, Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM, Multiple myeloma.
Shares Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM, Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple, Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi, Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM.
Shares A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme, A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult, All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo, Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi.
Shares A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas, All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo, China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame, Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex.
Shares Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM, Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares BCMA expression, BCMA, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares DREAMM-7, A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult, All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo, China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame.